Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Eiger BioPharmaceuticals, Inc. | d165876d8k.htm |
Exhibit 16.1
April 28, 2016
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentlemen:
We have read Item 4.01 of Form 8-K dated April 28, 2016, of Eiger BioPharmaceuticals (formerly Celladon Corporation) and are in agreement with the statements contained in paragraphs 2, 3, and 4 of Item 4.01(a), Changes in Registrant’s Certifying Accountant, on page 2 therein. We have no basis to agree or disagree with other statements of the registrant contained therein.
/s/ Ernst & Young LLP